15 December 2023 : Original article
Clinical Outcomes of Administration of Rituximab for Desensitization in Liver Transplant Patients with Preformed Donor-Specific Antibodies: A Single-Center Experience
Masato Shizuku
123ABCDEF*, Nobuhiko Kurata 1B, Kanta Jobara 1B, Yasuhiro Fujimoto 1B, Yasuhiro Ogura 1ABCDFG
DOI: 10.12659/AOT.941456
Ann Transplant 2023; 28:e941456
Table 3 Complement component 4d staining for patients with pDSA.
| Group | Case | Time after liver transplantation (Months) | ||||
|---|---|---|---|---|---|---|
| 1 Month | 3 Months | 6 Months | 12 Months | 24 Months | ||
| Rituximab (+) | Case 1 | Positive | Positive | Negative | Negative | |
| Case 2 | Positive | Negative | Negative | |||
| Case 3 | n.a. | Negative | ||||
| Case 4 | Negative | Negative | ||||
| Case 5 | n.a. | n.a. | n.a. | Negative | ||
| Case 6 | n.a. | n.a. | n.a. | Negative | ||
| Case 7 | Negative | Negative | ||||
| Case 8 | n.a. | n.a. | n.a. | Negative | ||
| Rituximab (−) | Case 9 | n.a. | n.a. | n.a. | n.a. | Negative |
| n.a. – not available. | ||||||